Empagliflozin Treatment is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Empagliflozin Treatment is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes james freeman diabetes freedom Sodium—glucose-cotransporter-2 (SGLT2) inhibitors reduce the risk of major adverse CV events and hospitalization Read more

Empagliflozin Treatment is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Empagliflozin Treatment is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes james freeman diabetes freedom Sodium—glucose-cotransporter-2 (SGLT2) inhibitors reduce the risk of major adverse CV events and hospitalization Read more